Yomali Ferreyra

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yomali

Contact Yomali, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

“Carry-Over” Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular

Feb 13, 2026 |

By Guillermo Valencia, Zaida Morante, Yomali Ferreyra

| preprints.org

Submitted: 12 February 2026 You are already at the latest version Background: Hormone receptor-positive/HER2-negative (HR+/HER2−) early breast cancer (EBC) presents a persistent risk of relapse, even beyond 5 years, driving adjuvant intensification strategies.

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Yomali

Contact Yomali, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Yomali Ferreyra

Get in touch with Yomali

Actions

Is this you?

Articles

“Carry-Over” Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular

Actions

Is this you?

Get in touch with Yomali